Stem Cell Clinic

Private clinics peddling of unproven stem cell treatments …

By Stem Cell Clinics

Stem cell science is an area of medical research that continues to offer great promise. But as this weeks paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, are exploiting regulatory gaps to sell so-called stem cell treatments without evidence that what they offer is effective or even safe.

Such unregulated direct-to-consumer advertising typically of cells obtained using liposuction-like methods not only places the health of individuals at risk, but could also undermine the legitimate development of stem cell-based therapies.

Many academic societies and professional medical organisations have raised concerns about these futile and often expensive cell therapies. Despite this, national regulators have typically been slow or ineffective in curtailing them.

As well as tighter regulations here, international regulators such as the World Health Organisation and the International Council on Harmonisation need to move on ensuring patients desperate for cures arent sold treatments with limited efficacy and unknown safety.

Hundreds of stem cell clinics post online claims that they have been able to treat patients suffering from a wide range of conditions. These include osteoarthritis, pain, spinal cord injury, multiple sclerosis, diabetes and infertility. The websites are high on rhetoric of science often using various accreditation, awards and other tokens to imply legitimacy but low on proof that they work.

Rather than producing independently verified results, these clinics rely on patient testimonials or unsubstantiated claims of improvement. In so doing these shonky clinics understate the risks to patient health associated with these unproven stem cell-based interventions.

Properly administered informed consent is often overlooked or ignored, so patients can be misled about the likelihood of success. In addition to heavy financial burdens imposed on patients and their families, there is often an opportunity cost because the time wasted in receiving futile stem cells diverts patients away from proven medicines.

The many recent reports of adverse outcomes demonstrate the risks of receiving unproven cell therapies are not trivial. In the USA three women were blinded following experimental stem cell treatment for macular degeneration (a degenerative eye disease that can cause blindness). One man was rendered a quadriplegic following a stem cell intervention for stroke. And a woman whose family sought treatment for her dementia died in Australia.

Other notorious cases involving the deaths of patients include the German government shutting down the X-Cell Centre and the Italian government closing the Stamina Foundation it had previously supported.

At present, the only recognised stem cell treatments are those utilising blood stem cells isolated from bone marrow, peripheral blood (the cellular components of blood such as red and white blood cells and platelets) or umbilical cord blood.

Hundreds of thousand of lives have been saved over the last half-century in patients with cancers such as leukaemia, lymphoma and multiple myeloma, as well as rare inherited immune and metabolic disorders.

A few types of cancer and autoimmune diseases may also benefit from blood stem cells in the context of chemotherapy. Different stem cells are also successfully used for corneal and skin grafting.

All other applications remain in the preclinical research phase or are just starting to be evaluated in clinical trials.

Further reading: Yes theres hope, but treating spinal injuries with stem cells is not a reality yet

Often dismissed by for-profit clinics as red tape hampering progress, the rigour of clinical trials allows for the collection of impartial evidence. Such information is usually required before a new drug or medical device is released into the marketplace. Unfortunately, in the case of for-profit stem cell clinics, their marketing has gazumped the scientific evidence.

Action is required on many fronts. Regulators at both an international and national level need to tackle regulatory loopholes and challenge unfounded marketing claims of businesses selling unproven stem cell interventions.

Researchers need to more clearly communicate their findings and the necessary next steps to responsibly take their science from the laboratory to the clinic. And they should acknowledge that this will take time.

Patients and their loved ones must be encouraged to seek advice from a trained reputable health care professional, someone who knows their medical history. They should think twice if someone is offering a treatment outside standards of practice.

The stakes are too high not to have these difficult conversations. If a stem cell treatment sounds too good to be true, it probably is.

For more information on recognised stem cell treatments visit the National Stem Cell Foundation of Australia and Stem Cells Australia, Choice Australia, EuroStemCell, International Society for Stem Cell Research, and International Society for Cellular Therapy.

Go here to see the original:
Private clinics peddling of unproven stem cell treatments ...

Embryonic Stem Cells – Definitions, Use, and Research

By Embryonic Stem Cells

Embryonic stem cells are cells that can give rise to all of the tissues types that form the human body.These stem cells are supporting research into new drugs, being explored for disease reversal, and being utilized to create healthy new tissue to heal injuries.

Embryonic stem cells are also controversial to produce, which has substantially limited their use.Learn more about these cells below.

In this article:

Embryonic stem cells are unique cells that exist in an early-stage embryo. During pregnancy, they develop into all of the cells and tissues that form the fetus and the newborn it grows into.

Embryonic or otherwise, stem cells differ from other types of cells and represent a fraction of the trillion of cells that compose the human body. Unlike regular cells, embryonic stem cells can reproduce. They can also turn into different kinds of cells, known as differentiation.

These pluripotent stem cells boast special characteristics that often make them better suited for therapeutic purposes than adult stem cells. Its helpful to remember that adult stem cells can also refer to those in newborns and children. The term simply means that the cells are sourced from a human being after a live birth This makes adult stem cell types non-controversial.

The embryos used to create embryonic stem cells come from in vitro fertilization clinics. These embryos would have otherwise been destroyed or discarded as medical waste by the fertility clinic, because they were not chosen for implantation into a mother or surrogate.

Because they are created from embryos, some people are opposed to research involving embryonic stem cells. Other groups, like the Michael J. Fox Foundation, have been highly favorable toward embryonic stem cell research, because the cells are versatile and have great potential for use in regenerative medicine to cure a range of diseases that burden the human race, such as Parkinsons disease, Alzheimers disease, multiple sclerosis (MS), and more.

To gauge what percentage of the public supports embryonic stem cell research, BioInformant posted a Twitter poll on September 16, 2018. The results of this poll are shown below, showing that slightly more than half of respondents support embryonic stem cell research (58%) and an astounding 84% of respondents either support embryonic stem cell research or think it depends on the situation.

Human embryonic stem cells (hESCs) are pluripotent cells that are derived from embryos at fertility clinics and provided with informed donor consent. Embryonic stem cells are usually harvested shortly after fertilization (within 4-5 days) by transferring the inner cell mass of the blastocyst into a cell culture medium, so that the cells can be multiplied in a laboratory.

Pluripotent cells can give rise to all of the cell types that form the human body, making them very powerful for use within regenerative medicine applications.

As the name suggests, human embryonic stem cells are derived from human embryos, which makes them controversial to produce. Thankfully, these cells are only produced from embryos that would otherwise treated as biological waste produced as a byproduct of the assisted fertility process at fertility clinics.

In contrast, embryonic stem cells can also be derived animal sources, such as from mice, rats, monkeys, and more. These animal derived embryonic stem cells are substantially less controversial for use in research applications. Unfortunately, they also have few therapeutic applications, because there are immunological issues associated with using animal cells within humans.

If @UWMadison is the birthplace of human embryonic stem cells, then the Primate Research Center is the cradle. Marina Emborg A starring role for nonhuman primates in the stem cell story fantastic article https://t.co/JNXDZ26KGh pic.twitter.com/h1ZQNYbnL1

Speaking of Research (@SpeakofResearch) September 13, 2018

Researchers harvest human embryonic stem cells from a blastocyst. Thats the scientific name for an embryo in its earliest form, usually 4-5 days past the fertilization stage. In traditional human pregnancy, the blastocyst stage occurs before the embryo reaches and implants within the mothers uterine wall. At this blastocyst stage, the young embryo has about 150 cells. That makes it easy to isolate them for harvesting.

Blastocyst embryos used for harvesting come from embryos created in fertility clinics, not from a womans uterus. Researchers harvest them with the permission of the sperm and egg donors. Once created, the blastocyst embryos can be preserved indefinitely under laboratory conditions.

Researchers harvest the embryo stem cell at the Day 4 or 5 stage. This time frame is crucial, because it is just after the embryo begins dividing multiple cells within itself, but before those cells begin to differentiate.

To differentiate, as the name suggests, means that the cells begin to become specific to one of the three germ layers. However, an inner cell mass (ICM) does form, within a protective outer layer. The cells get harvested from the ICM after scientists penetrate the outer layer.

Scientists first isolated embryonic stem cells in mice in 1981. Much later, they isolated human embryonic stem cells in 1998. Ethical concerns caused much of that gap in research. For moral and practical reasons, the cellsneededto be harvested from embryos thatdidnt come from a pregnant woman.

Fortunately, by the late1990sfertility clinics perfected many new techniques. Those breakthroughs not only meant higher success rates for hopeful couples, they also created more viable embryos from which stem cells could be extracted. The clinics reportedly had about 11,200 embryos in frozen storage that would otherwise be discarded. Instead, the clinics donated some for stem cell research.

Scientists cleared the second major research hurdle in 2001 when the federal government decided to fund embryonic stem cell research. This support allowed various research facilities to obtain and study the embryos.

The breakthrough came at an exciting time, because researchers had only recently learned how to extract the needed embryonic stem cells. The mouse-related discovery in 1981 was important. However, those cells differ too much from human embryonic stem cells to put the knowledge to use. In the interim, researcher achieved breakthroughs with other primates.

Scientists value embryonic stem cells because of theirpluripotent properties. For the non-scientists among us, that means they cells are highly versatile and capable of becoming a wide range of cell types. Many stem cells can only produce exact copies of themselves for example, blood cells to blood cells, bone cells to bone cells, and so forth. apluripotentstem cell is defined as a cell that can change itself into nearly any cell or tissue type within the human body.

In practice, this allows scientists to turn embryonic stem cells into any part of the body. Cells develop in layers, known as germ layers. Humans have three germ layers. The outermost, the ectoderm, consists of skin and nervous system. Next, the mesoderm, make up bones, blood, muscles,and the genial system. The innermost germ cell layer, theendoterm, includes lung and digestive system cells. Taken together, adult humans have 220 different types of cells within those three layers.

Embryonic stem cells keep generating new cells, making them useful. These reproductive abilities mean the stem cells ultimately form tissue to can be used to help patients. The tissues can also be used by scientists to conduct medical research.

While embryonic stem cells are pluripotent stem cells, there are also two other types of stem cells: totipotent and multipotent cells. What is the difference between they cell types? The answer is simple.

Totipotentstem cells are the most versatile stem cell type, because they are formed shortly after fertilization of an egg cell by a sperm cell. They can become all of the cells of the human body, as well as the cells of the embryo and developing fetus.At about four days into development, these totipotent cells specialize slightly, becoming pluripotent stem cells, such as the embryonic stem cell.

Later, multipotent stem cells form, which are again more limited in what they can become.They cells types usually prefer to become cells of a certain class or category.

For example, hematopoieticstem cells (HSCs) are a type of multipotent stem cell that prefer to become cells of the blood and immune system, although it it possible to induce them to become other cell types.

Scientists only recently began to understand how many diseases and conditions embryonic stem cells may be able to treat. Research is still ongoing. Because so many health problems involve the dysfuntion or death of cells, human embryonic stem cells may be able to reverse the progress of these diseases.

In the future embryonic stem cells may contribute to the treatment of Parkinsons disease, heart disease, diabetes, spinal cord injuries, vision problems, or other diseases and conditions.

How Can Stem Cell Therapy Help You? | What Diseases Can Be Treated with Stem Cell Therapy https://t.co/lqiH5Z6Xhi

BioInformant (@StemCellMarket) June 23, 2018

Suitable subjects for testing present a major stumbling block toward radical breakthroughs in pharmacology. Early versions of medicinal drugs and surgical procedures carry potential side effects that may not come out until testing actually occurs. This is obviously problematic for any human subjects, especially for those already frail from the disease or injury.

That is why human embryonic stem cells present a radical opportunity for new breakthroughs in drug therapy and surgical procedures. Scientists can grow healthy tissue from embryonic stem cells to see how that tissue responds to these therapies. They can also give that tissue specific disorders, then attempt to cure it with new medical breakthroughs.

Human embryonic stem cells have the ability to transform into other cells. From those new cells, scientists can create heart tissue, bone marrow tissue, blood samples or other body parts which they need to test. In doing so, they can avoid experimenting on patients.

In addition to embryonic stem cells, several broad categories of stem cells exist, including:

Stem cell research has been going on for over 50 years because stem cells have a unique ability to divide and replicate repeatedly. In addition, their unspecialized nature makes them of great interest for regenerative medicine applications.

Adult stem cells also hold more great promise. In healthy humans, adult stem cells produce new cells when needed, to maintain normal functions and repair minor wounds and disorders. However, they are considered less versatile, because they cannot differentiate into all tissue types that compose the human body like embryonic stem cells.

Adult stem cells typically have a preference to become certain tissues within the human body. For example, hematopoietic stem cells (HSCs) are a widely researched adult stem cell type. Although HSCs prefer to become cells of the blood and immune system, they can sometimes be coaxed to become other cell types.

Another example of the utility of adult stem cells is the success of bone marrow transplants. Bone marrow transplants treat patients with cancer whose immune systems have been compromised by chemotherapy or radiation. A bone marrow transplant from a donor or from the patient, prior to treatment uses bone marrow stem cells to help generate new cell production.

Over time, researchers have discovered adult stem cells in many sites throughout the human body. Adult stem cells are now known to exist in the blood, bone marrow, fat (adipose) tissue, dental pulp, neural tissue, and many other sites.

These stem cells are capable of positively affecting a wide range of diseases through either tissue repair or signalling mechanisms. Particular stem cells types, like mesenchymal stem cells, can lower inflammation, reduce scarring, and improve immune function.

What changed? Until recently, adult stem cells were considered inherently limited, because they do not differentiate into all of the cells that compose the human body. However, researchers have found a variety of ways to activate both cell division and differentiation. This ability to grow more healthy tissue in laboratory conditions could substantially alter the future of medicine.

Access to embryonic stem cells is inherently limited to the number of available samples from fertility clinics. Yet adult donors are more plentiful. This is particularly true if a patient can act as his or her own donor.

What are embryonic stem cells and how can they help heal diseases? Watch the video below to learn more:

What do you want to know about embryonic stem cells? Share your thoughts with us below.

Up Next:How to Find a Stem Cell Clinical Trial for Your Condition?

Embryonic Stem Cells Definitions, Use, and Research

The rest is here:
Embryonic Stem Cells - Definitions, Use, and Research

Will Embryonic Stem Cells Ever Cure Anything? – MIT …

By Embryonic Stem Cells

When his son Sam was diagnosed with type 1 diabetes at six months of age, Doug Melton was incredulous. I remember at night, my wife and I pricking his heel, and saying No, this cant be, this cant be, he says. It felt like we had lost the lottery.

Later, his daughter would receive the same diagnosis. By then, Melton had already dropped what he was doingstudying frog eggs at Harvardand launched an effort to grow pancreatic cells from scratch in his lab. The beta cells of the pancreas are the ones killed off in type 1 diabetes, and Melton reasoned he could replace them using new tissue manufactured from embryonic stem cells.

Meltons effort, involving a 30-person lab at Harvard and a startup company, Semma Therapeutics, which he named after his children, Sam and Emma, is one of the most costly and sustained efforts to turn stem cells into transplantable tissue, an attempt that Melton admits has been full of false starts and dead ends. The public definitely doesnt appreciate that much of science is failure, he says.

In fact, no field of biotechnology has promised more and delivered less in the way of treatments than embryonic stem cells. Only a handful of human studies has ever been carried out, without significant results. The cells, culled from IVF embryos, are capable of developing into any other tissue type in the body, and therefore promise an unlimited supply of replacement tissue.

Sounds simple, but it hasnt been. It took Melton and his team 15 years to unveil each molecular step required to coax a stem cell into a pancreatic beta cell able to sense glucose and secrete insulin. The recipe uses a cocktail of chemicals and a three-dimensional incubation system, tall spinning flasks brewing what looks like murky red Gatorade, that within 30 days can direct the differentiation of stem cells into fully functional beta cells.

Earlier this year, Melton was finally able to demonstrate he could control blood glucose levels of mice for six months using transplants of human beta cells. He thinks he can do that in humans and stretch the therapeutic effect out to a year, a goal thats been turned over to Semma, which is designing an implantable pouch to hold and protect the cells.

Over the last two years, Semma has raised just under $50 million from venture capital firms, California's stem-cell agency, and corporate partners including Novartis and Medtronic. William Sahlman, a Harvard Business School professor who sits on Semma's board, says people are prepared to put very large amounts of money on the experiments. One reason: the global market for insulin exceeds $30 billion a year. Tests strips and monitors might double that.

Because their bodies mount an immune attack on the pancreatic cells that regulate blood glucose, type 1 diabetics are constantly measuring their blood sugar levels with finger pricks and injecting insulin multiple times a day. Their lives can be foreshortened by more than a decade. You could almost say that cellular therapy is the natural solution, Melton says. Its not the technological solution. Its not the Google solution. Its natures solution to the problem. Youre providing the cell which is missing.

Several companies are attempting a tech solution, however, by using electronics to build an artificial pancreas that combines a continuous glucose monitor, an insulin pump, and a sensor with an algorithm to control dosing. Medtronic is nearing FDA approval with one such closed loop system; its smartphone-sized MiniMed 670G performed well in early trials. One of Googles sister companies, Verily, is itself developing glucose-sensing contact lenses and ultra-thin sensors.

San Diego-based ViaCyte, working with Johnson & Johnson, was first to try pancreatic cells derived from embryos in people. It has built an implantable packet of immature cells, which it hopes will differentiate inside the body, and last year opened a clinical trial to test the idea.

Semma also thinks it needs to turn embryonic stem cells into not only insulin-secreting beta cells, but a full-fledged isletthe cluster of cells that includes the alpha, beta, delta, and ancillary cells normally found in a pancreas. Thats a complex objective but one that closely mimics biology. Theres a reason during evolution that these cells are adjacent to one another, says Felicia Pagliuca, Semma's cofounder and a veteran of Meltons lab.

In order to deliver their lab-grown islet to diabetics, Semma is developing prototypes of an iPhone-sized, retrievable packet whose materials insulate it from the immune system, so that patients dont have to take immune-suppressing drugs, as they would if they had a kidney transplant. Christopher Thanos, Semma's vice president of delivery, says his team is modeling physiological processes inside and around the device to experiment with different rates of oxygen, nutrients, and insulin diffusion.

Some outside experts think protecting the cells will not be possible. I'm not optimistic that encapsulation is going to provide the answer, says David Cooper, a professor of surgery at the University of Pittsburgh working on growing human islets in pigs. I personally don't think a device is ever going to be successful. It's impossible to keep all the injurious agents out, he says, referring to the cytokines, antibodies, and other compounds the body releases in response to a foreign body. There's really very little evidence that a capsule can protect you completely from an immune response.

The prospect of surgery every year for the rest of your life is also a practical concern. How many diabetics would sign up for 50, 60, 70 surgeries over the course of a lifetime? What will be the effect of repeated scarring around the surgical site? Melton says the inconvenience of surgery has to be weighed against the thousands of finger pricks and injections that diabetics must administer every year. My kids say once a month they wouldnt hesitate. I think thats a bit extreme, he says. But if it was twice a year, I think thats a go.

If the device does not work, Semma has a backup plan of sorts. It received a $5 million grant from CIRM, the California stem-cell agency, to manufacture islets out of a patient's own tissue using induced pluripotent stem cells. That is a process by which adult cells, like skin cells, are reprogrammed into stem cells. Such matching cells wouldnt be rejected by the body as foreignand might not need as much protectionalthough they probably would not avoid damage by the processes that cause type 1 diabetes in the first place. Semma believes they could help a fraction of patients whose diabetes has different causes.

Semma still has no timeline for when its implantable biotech pancreas could be ready. That means Melton's children will have to wait a while longer. Im sorry it takes so long, says Melton, but it is going to work.

View post:
Will Embryonic Stem Cells Ever Cure Anything? - MIT ...

Adult Stem Cell Therapy – regenocyte.com

By Adult Stem Cells

For more than 40 years, adult stem cells have been used to treat cancer patients. Recent advancements in adult stem cell therapy have been astounding. Cells from an ill patient are being used as part of the treatment. There is no possibility of the body rejecting the new tissue formed, making stem cell treatment safe and effective in achieving positive medical outcomes. It is important to note that adult stem cell therapy is not controversial because it involves the use of a patients own tissues and NOT derived from embryos.

Clinical results from cardiac, pulmonary, neurological, and vascular procedures have shown that the adult stem cell procedures are as safe as traditional procedures and are complimentary to current medical practice.

Visit our Facebook Page and read more about our real life patients and how adult stem cell therapy has changed their lives.

Adult stem cells are extracted from the patients bone marrow and fat (adipose). At Intercellular Sciences, the naturally occurring stem cells in the blood are cultivated into millions of Regenocyte Adult Stem Cells. The Regenocyte Stem Cells are produced in our international treatment center and are administered into the area of need for the patient. Once injected, they stimulate tissue re-growth and greater blood flow to the affected areas. The goal of the treatment is to replace damaged cells and to promote the growth of new blood vessels and tissues in order to help the target organ function at a greater capacity. There is no risk of rejection since the Adult Stem Cells received are directly from the patient. Regenocyte Adult Stem Cell Therapy is safe, highly effective and presents minimal risk.

Stem Cell Treatment: Cardiac

Stem Cell Treatment: Pulmonary

Stem Cell Treatment: Vascular

Stem Cell Treatment: Neurologic

If you think that adult stem cell therapy treatment may be out of reach for your health issues, it is not. Treatment is available today. Regenocyte Adult Stem Cell Therapy results have exceeded expectations. For more information on Intercellular Sciences treatments, results, and updates on advances in adult stem cell therapy, please register for our newsletter today.

To find out more today, click here or call us at (866) 216-5710

Read this article:
Adult Stem Cell Therapy - regenocyte.com

Summary: What is an Adult Stem Cell? | Stem Cells Portal …

By Adult Stem Cells

Adult stem cells can proliferate without differentiating for a long period (a characteristic referred to as long-term self-renewal), and they can give rise to mature cell types that have characteristic shapes and specialized functions.

Some adult stem cells have the capability to differentiate into tissues other than the ones from which they originated; this is referred to as plasticity.

Adult stem cells are rare. Often they are difficult to identify and their origins are not known. Current methods for characterizing adult stem cells are dependent on determining cell surface markers and observations about their differentiation patterns in test tubes and culture dishes.

To date, published scientific literature indicates that adult stem cells have been derived from brain, bone marrow, peripheral blood, dental pulp, spinal cord, blood vessels, skeletal muscle, epithelia of the skin and digestive system, cornea, retina, liver, and pancreas; thus, adult stem cells have been found in tissues that develop from all three embryonic germ layers.

Hematopoietic stem cells from bone marrow are the most studied and used for clinical applications in restoring various blood and immune components to the bone marrow via transplantation. There are at least two other populations of adult stem cells that have been identified from bone marrow and blood.

Several populations of adult stem cells have been identified in the brain, particularly the hippocampus. Their function is unknown. Proliferation and differentiation of brain stem cells are influenced by various growth factors.

There are now several reports of adult stem cells in other tissues (muscle, blood, and fat) that demonstrate plasticity. Very few published research reports on plasticity of adult stem cells have, however, included clonality studies. That is, there is limited evidence that a single adult stem cell or genetically identical line of adult stem cells demonstrates plasticity.

Rarely have experiments that claim plasticity demonstrated that the adult stem cells have generated mature, fully functional cells or that the cells have restored lost function in vivo.

What are the sources of adult stem cells in the body? Are they "leftover" embryonic stem cells, or do they arise in some other way? And if the latter is truewhich seems to be the caseexactly how do adult stem cells arise, and why do they remain in an undifferentiated state, when all the cells around them have differentiated?

Is it possible to manipulate adult stem cells to increase their ability to proliferate in vitro, so that adult stem cells can be used as a sufficient source of tissue for transplants?

How many kinds of adult stem cells exist, and in which tissues do they exist? Evidence is accumulating that, although they occur in small numbers, adult stem cells are present in many differentiated tissues.

What is the best evidence that adult stem cells show plasticity and generate cell types of other tissues?

Is it possible to manipulate adult stem cells to increase their ability to proliferate in vitro so that adult stem cells can be used as a sufficient source of tissue for transplants?

Is there a universal stem cell? An emerging concept is that, in adult mammals, there may be a population of "universal" stem cells. Although largely theoretical, the concept has some experimental basis. A candidate, universal adult stem cell may be one that circulates in the blood stream, can escape from the blood, and populate various adult tissues. In more than one experimental system, researchers have noted that dividing cells in adult tissues often appear near a blood vessel, such as candidate stem cells in the hippocampus, a region of the brain [75].

Do adult stem cells exhibit plasticity as a normal event in vivo? If so, is this true of all adult stem cells? What are the signals that regulate the proliferation and differentiation of stem cells that demonstrate plasticity?

Excerpt from:
Summary: What is an Adult Stem Cell? | Stem Cells Portal ...

Stem Cell Treatment for Ataxia – Stem Cell Treatment Now

By Stem Cell Treatment

How does ataxia affect the patient? The disease is characterized by progressively disabling clinical manifestations. Patients show symptoms of gait instability or dysarthria and may begin to fall without warning. Gradually they present progressive limitations in their activities, lose the ability to walk, become bedridden and fully dependent. Other clinical manifestations include astasia, impaired fine motor skillsand intention tremor (cerebellar tremor). The cerebellar syndrome is often associated with other neurological signs such as pyramidal or extrapyramidal signs, ophthalmoplegia, and cognitive impairment.

How to diagnose ataxia? Most people dont know what ataxia is and may overlook the early symptoms. Anyone with progressive gait disorder or imbalance should be evaluated by a neurologist. MRI is recommended in all cases. If a treatable cause is not discovered, a gene test should be done. In about 60 percent of the cases, the gene test will determine the type of ataxia.

What is the efficacy of conventionaltreatments? Until now, conventional treatments are generally used to alleviate the symptoms, not the disease itself. The movement disorders can be managed using pharmacological, physical and occupational therapies to minimize the damage and to promote the mobility as long as possible but overall current treatment remains retardant.

What are the difference between autosomal dominant and autosomal recessive ataxias? Autosomal dominant and autosomal recessive ataxias are hereditary ataxias, and spinocerebellar ataxia (SCA) and Friedreich's ataxia (FRDA) are the most common forms of hereditary ataxia. Autosomal dominant genes express themselves when present. Autosomal recessive genes will only express themselves when in the homozygous state -- i.e., both genes in the gene pair are the recessive gene form. Thus, recessive genes can be "carried" by those whose phenotype does not exhibit the gene characteristic, while dominant genes cannot be "carried". Therefore, generally autosomal dominant ataxias are easier to express andat a higher morbiditythan autosomal recessive ataxias.

What is the role of Purkinje cells, where can we find those cells ? Purkinjecellsare a type of neuron found in the cerebellar cortex, at the base of the brain.They are among the largest neurons and are responsible for most of the electrochemical signaling in the cerebellum. ThePurkinjecellsand the cerebellum are essential to the body's motor function. Disorders involving thePurkinjecellsusually negatively affect the patient's movements.

View post:
Stem Cell Treatment for Ataxia - Stem Cell Treatment Now

Stem Cell Therapy | Lighthouse Medical Center …

By Stem Cell Medical Center

Therapeutic STEM CELL THERAPY What is Regenerative Medicine & Therapeutic stem cell Treatment?

Wharton's Jelly or umbilical cord tissue contain many Regenerative factors like anti inflammatory cytokines, rowth factors, hyaluronic acid & Mesenchymal Stem Cells.

Lighthouse Medical Center offers treatments that are designed to kick start your own body's healing. Not a temporary fix or to act as a mask for pain. By building on what your body can innately do, and stimulating it in a very powerful way through a protocol of injections and therapies, stem cell and regenerative medicine can provide complete and total healing without the stress, cost, and downtime of surgery.

Featuring premium regenerative therapies including:CoreCyte, AmnioCyte Plus, PolyCyte and PRP therapeuticstem cell therapies, our treatments provide real healing for our patients!We use Cell products that contain Mesenchymal Stem Cells.

Join us for aFREE SEMINAR on stem cell therapy! Fill out the contact information below and we will reach out to you ! Lighthouse Medical Center has 1-2 seminars monthly.

Therapeutic stem cells are the body's raw materials cells from which all other cells with specialized functions are generated(Mayoclinic.org).

Over time our tissue can lose functionality due to age, injury, and disease. That can mean longer healing time, cellular aging and changing chemical environments. Fortunately, each person is born with building blocks capable of repairing and replenishing tissue.

We here at Lighthouse Medical Center use therapeutic stem cells and tissue products that are processed in an FDAregistered lab. The minimally manipulated tissue products are prepared to utilize proprietary extraction methods that reduce the loss of important cytokines, growth factors, proteins, and biomolecules.

Lighthouse Medical Center offers the mostinnovative techniques in Therapeutic stem cell and regenerative medicine therapies. We offer a plethora of therapies for various orthopedic conditions and injuries.

Therapeutic Stem cell and regenerative medicine at Lighthouse Medical Center includes the collection and use of therapeutic stem cells toincrease function, reduce the rate of degeneration, reduce inflammation, reduce scar tissue and promote healing in themusculoskeletal system, including: shoulders, elbows, wrists, hips, knees, ankles, neck and the back.

Just to name a few;

Mesenchymal stem cell

therapy also helps with :

Shoulder pain

Knee pain

Joint back

Back pain

Hip pain

osteoarthritis

If you have tennis elbow,

golfers elbow, plantar fasciitis

and rotator cuff injuriesand

are lookingfor a solution to

the challenges you face,

regenerative and Therapeutic

stem cell medicine therapies

might be exactly whats right

for you.

Dr. Beylers 3 Month Therapeutic Stem Cell Therapy Testimony

Knee And Hip One MonthTherapeutic Stem Cell Testimony

More:
Stem Cell Therapy | Lighthouse Medical Center ...

Braselton Georgia Stem Cell Therapy – Revive Medical Center

By Stem Cell Medical Center

Stem cells have been in the news a lot lately, and they have already proven their value in clinical trials and cutting edge medical treatments. Unlike other kinds of cells, stem cells have the ability to transform themselves. These unique cells can become any other type of cell, and that ability is what gives them their power.

Stem cells have been called many things, from the master cell of the human body to the building block of life. In the end, however, it does not matter what they are called what really matters is how they work.

There is a detailed scientific explanation of the stem cell, but what you really need to know is that these cells are undifferentiated. That undifferentiated status means that stem cells can transform themselves into virtually any type of cell in the body. Scientific studies and clinical trials have already shown that stem cells injected into heart muscle can become heart cells, and that adding stem cells to the brain can stimulate the growth of brain tissue.

In addition to their other abilities, stem cells may be a real alternative to invasive surgeries. If your doctor has suggested surgery to treat an exercise injury or other ailment, you owe it to yourself to check out stem cell therapy as an alternative.

Surgery can be effective, but there are significant downsides, including long recovery times and possible complications. Stem cells, on the other hand, can provide the effectiveness of surgery with none of the downside risk. If you think stem cells could be the answer, just give Revive Medical Center a call. Our stem cell therapy experts can assess the situation and provide a custom recommendation to treat your injury.

At Revive Medical Center, most of our Braselton, Georgia area residents are able to return to work the very same day. Instead of spending days in the hospital and weeks recuperating at home, our stem cell therapy patients can enjoy their lives and get back to work fast, with minimal downtime and no pain.

Professional athletes are already using stem cells to improve their game and get a new lease on life, and now Braselton area residents can do the same. Not all stem treatments are the same, and Revive Medical Center strives to be the best. Whether you have suffered an injury or just want to avoid surgery, you owe it to yourself to check out the power of stem cells.

More here:
Braselton Georgia Stem Cell Therapy - Revive Medical Center

Induced Pluripotent Stem Cells – Embryo Project

By Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells (iPSCs) are cells derived from non-pluripotent cells, such as adult somatic cells, that have been genetically manipulated so as to return to an undifferentiated, pluripotent state. Research on iPSCs, initiated by Shinya Yamanaka in 2006 and extended by James Thompson in 2007, has so far revealed the same properties as embryonic stem cells (ESCs), making their discovery potentially very beneficial for scientists and ethicists alike. By avoiding the destruction of embryos and the complicated technique and resource requirements of ESCs, iPSCs may prove more practical and attractive than ESC research in the study of pluripotent stem cells.

Yamanaka and his team were able to revert the differentiated cells to a pluripotent stage by using a retrovirus to insert specific genes known to be active in ESCs into the cells genome. Originally performed with mouse cells by Yamanaka and his team at Japans Kyoto University, both Yamanakas group and James Thompsons research team at University of Wisconsin, Madison, extended the technique to human somatic cells in November of 2007. A variety of genes and gene families have been identified as key components of a successful induction to the pluripotent state: Oct-3/4, the Sox family, the Klf family, the Myc family, Nanog, and LIN28. Additional genes that are expressed in ESCs include GDF3, REX1, FGF4, ESG1, DPPA2, DPPA4, and hTERT.

Unlike ESCs, iPSCs do not require embryos or even eggs from female donors a feature that has made them very appealing to scientists wishing to do work on pluripotent stem cells, which has heretofore been restricted in the United States and elsewhere due to ethical concerns and legal limitations. Though early work with iPSCs failed to produce living mice from embryos containing iPSCs, several research teams in the US and Japan achieved success after injecting iPSCs into developing embryos. The insertion of iPSCs into mice also originally caused high rates of cancerous tumors, but removal of the c-Myc genes from the retrovirus apparently eliminates the unusually high risk of cancer, according to further 2008 research by Yamanaka and his team.

Despite the genetic alteration involved in producing iPSCs, in most other aspects they are as yet indistinguishable from ESCs. In fact, the skills and resources required to produce iPSCs are significantly less labor-intensive and costly than those required for ESCs, in that most scientists with experience in genetic reprogramming can produce iPSCs. Neither iPSCs nor ESCs have yet been used in clinical treatments, though many researchers believe that undifferentiated cells hold even more potential for therapeutic applications than do adult stem cells, which are already used in a variety of therapies.

Immediately hailed by the media as the next step toward personalized medicine and the answer to the ESC research controversy, many researchers, ethicists, writers, and anti-ESC research groups have called for an end to or reduction in ESC research and funding. Scientists in the field, including some of the teams working with iPSCs, caution that it is still too soon to assume that iPSCs can replace ESCs in clinical potential and that ESC research will continue to be important in increasing sciences understanding of developmental biology. In addition, some scholars caution that iPSCs may eventually be altered to reach the totipotent state, which could nullify their ethical simplicity and place them on equal footing with embryos.

Though iPSCs show a great deal of potential for stem cell therapies and clinical applications, scientists are still in the fledgling research stages for this technology. If they surpass ESCs in practicality and success rates without totipotent capabilities, however, iPSCs may lay much of the ethical controversy surrounding ESC research to rest.

Brind'Amour, Katherine, "Induced Pluripotent Stem Cells".

(2010-05-06). ISSN: 1940-5030 http://embryo.asu.edu/handle/10776/1974.

Arizona State University. School of Life Sciences. Center for Biology and Society. Embryo Project Encyclopedia.

Arizona Board of Regents Licensed as Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported (CC BY-NC-SA 3.0) http://creativecommons.org/licenses/by-nc-sa/3.0/

Read the original post:
Induced Pluripotent Stem Cells - Embryo Project

A safe and potent anti-CD19 CAR T cell therapy | Nature …

By Uncategorized

Imai, C. et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18, 676684 (2004).

Campana, D., Schwarz, H. & Imai, C. 4-1BB chimeric antigen receptors. Cancer J. 20, 134140 (2014).

Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 14531464 (2009).

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725733 (2011).

Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 15071517 (2014).

Maude, S. L. P. et al. Efficacy and safety of CTL019 in the first US phase II multicenter trial in pediatric relapsed/refractory acute lymphoblastic leukemia: results of an interim analysis. Blood 128, 2801 (2016).

Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 25452554 (2017).

Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 4556 (2019).

Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA 90, 720724 (1993).

Brentjens, R. J. et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 13, 54265435 (2007).

Kochenderfer, J. N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 40994102 (2010).

Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).

Kochenderfer, J. N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 27092720 (2012).

Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra138 (2013).

Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188195 (2014).

Turtle, C. J. et al. Immunotherapy of non-Hodgkins lymphoma with a defined ratio of CD8+ and CD4+CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl. Med. 8, 355ra116 (2016).

Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 21232138 (2016).

Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapyassessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 4762 (2018).

Brudno, J. N. & Kochenderfer, J. N. Chimeric antigen receptor T-cell therapies for lymphoma. Nat. Rev. Clin. Oncol. 15, 3146 (2018).

Kelley, L. A. & Sternberg, M. J. Protein structure prediction on the Web: a case study using the Phyre server. Nat. Protoc. 4, 363371 (2009).

Wang, X. et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 12551263 (2011).

Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731738 (2018).

Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739748 (2018).

Kochenderfer, J. N. et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540549 (2015).

Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).

Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664679 (2016).

Brudno, J. N. & Kochenderfer, J. N. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127, 33213330 (2016).

Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 12901297 (2011).

Farber, D. L., Yudanin, N. A. & Restifo, N. P. Human memory T cells: generation, compartmentalization and homeostasis. Nat. Rev. Immunol. 14, 2435 (2014).

Wang, A. et al. The stoichiometric production of IL-2 and IFN- mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci. Transl. Med. 4, 149ra120 (2012).

Hudecek, M. et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res. 3, 125135 (2015).

Alabanza, L. et al. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol. Ther. 25, 24522465 (2017).

Waage, A., Brandtzaeg, P., Halstensen, A., Kierulf, P. & Espevik, T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J. Exp. Med. 169, 333338 (1989).

Oliver, J. C. et al. Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. Lymphokine Cytokine Res. 12, 115120 (1993).

Salter, A. I. et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci. Signal. 11, eaat6753 (2018).

Marasco, W. A., Haseltine, W. A. & Chen, S. Y. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc. Natl Acad. Sci. USA 90, 78897893 (1993).

Shen, L., Evel-Kabler, K., Strube, R. & Chen, S. Y. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol. 22, 15461553 (2004).

Song, X. T. et al. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat. Med. 14, 258265 (2008).

Wang, D. et al. Efficacy of intracellular immune checkpoint-silenced DC vaccine. JCI Insight 3, e98368 (2018).

Jiang, X. X. et al. Control of B cell development by the histone H2A deubiquitinase MYSM1. Immunity 35, 883896 (2011).

Read the original:
A safe and potent anti-CD19 CAR T cell therapy | Nature ...

→←